TY - JOUR
T1 - Topoisomerase-I inhibitors in gynecologic tumors
AU - Haluska, P.
AU - Rubin, E.
AU - Verschraegen, C. F.
PY - 1999
Y1 - 1999
N2 - The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13% and 25%. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.
AB - The first section of this article reviews recent studies that have clarified both the cellular role of topoisomerase I and the mechanisms of cytotoxicity of the topoisomerase inhibitors, the camptothecins. Different analogs of this new class of antitumor drug have been studied using various dose schedules in the treatment of refractory or recurrent gynecologic cancer. Response rates are between 13% and 25%. The main toxic effects are hematologic and gastrointestinal, the latter remains problematic. Radiotherapy, alkylate, platinum analogues, and topoisomerase II inhibitors are currently being studied in combination with camptothecins.
UR - http://www.scopus.com/inward/record.url?scp=0033044401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033044401&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70153-2
DO - 10.1016/S0889-8588(05)70153-2
M3 - Article
C2 - 10080069
AN - SCOPUS:0033044401
SN - 0889-8588
VL - 13
SP - 43
EP - 61
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 1
ER -